View Post

Mother’s HPV Status Impacts Oral HPV Persistence for Offspring

In COVID-19, Latest News by Precision Vaccinations

The results of a new study focused on 0ral Human Papillomavirus (HPV) infections in children during the first six years of life indicate that HPV infection can be acquired non-sexually and is already common at an early age.
This longitudinal study found children acquire their first oral HPV infection at an early age. 
The US Centers for Disease Control and Prevention (CDC) published an Early Release, Volume 27, Number 3, March 2021, based on an extensive study in Finland.

View Post

Protein-based COVID-19 Vaccine Candidate Switches Adjuvant Partner

In COVID-19, Latest News by Precision Vaccinations

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced their plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted, with CpG 1018 plus alum in the first half of 2021.
In a press release on February 1, 2021, the companies stated an interim analysis for vaccine efficacy may become available in the middle of 2021.
Clover stated it expects to produce hundreds of millions of vaccine doses in 2021 and up to 1 billion vaccine doses in peak annual production as required by global demand.

View Post

Protein-based COVID-19 Vaccine Candidate Narrows Adjuvant Partner

In COVID-19, Latest News by Precision Vaccinations

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced their plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted, with CpG 1018 plus alum in the first half of 2021.
In a press release on February 1, 2021, the companies stated an interim analysis for vaccine efficacy may become available in the middle of 2021.
Clover stated it expects to produce hundreds of millions of vaccine doses in 2021 and up to 1 billion vaccine doses in peak annual production as required by global demand.